专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20090281064A1 SOLID PHARMACEUTICAL DOSAGE FORMS COMPRISING BISPHOSPHONATES AND MODIFIED AMINO ACID CARRIERS 审中-公开
标题翻译：含有二磷酸酯和改性氨基酸载体的固体药物剂型
公开(公告)号：US20090281064A1
公开(公告)日：2009-11-12
申请号：US12504484
申请日：2009-07-16
申请人： Hashim Ahmed , Lewis Bender , Martin Howard Infeld , Shingai Majuru , Wantanee Phuapradit , Navnit Hargovindas Shah , Zhongshui Yu
发明人： Hashim Ahmed , Lewis Bender , Martin Howard Infeld , Shingai Majuru , Wantanee Phuapradit , Navnit Hargovindas Shah , Zhongshui Yu
IPC分类号： A61K31/66
CPC分类号： A61K9/2013 , A61K9/1617 , A61K9/2866 , A61K9/48 , A61K9/501 , A61K31/663 , A61K31/675 , A61K47/183 , A61K47/32
摘要： The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone, and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain. The present invention also provides a method for treating these diseases employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.
摘要翻译：本发明提供用于口服给药的新型固体药物剂型，其包含双膦酸盐或其药学上可接受的盐，当双膦酸盐单独口服时，双膦酸盐以不具有治疗效果的量存在，和修饰的氨基酸载体，或其修饰的氨基酸载体的存在量有效地促进胃肠道中双膦酸盐的吸收，使得双膦酸盐具有治疗上的有效性。二膦酸酯与改性氨基酸载体的比率分别为约1:30至约1:1。这些新型固体药物剂型可用于治疗或控制钙代谢中的骨疾病和特定疾病，包括例如骨质疏松症，癌症高钙血症和转移性骨痛的治疗。本发明还提供了使用固体药物剂型治疗这些疾病的方法和制备药物剂型的方法。

2. 发明申请

US20070027769A1 Method for redeeming frequent flier mileage 审中-公开
标题翻译：兑换频繁里程的方法
公开(公告)号：US20070027769A1
公开(公告)日：2007-02-01
申请号：US11495373
申请日：2006-07-28
申请人： Lewis Bender
发明人： Lewis Bender
IPC分类号： G06Q30/00 , G06Q10/00
CPC分类号： G06Q20/06 , G06Q10/02 , G06Q30/02 , G06Q30/0222 , G06Q30/0226
摘要： A method, system and computer program for redeeming frequent flier miles to purchase a good or service are provided. An exemplary embodiment of the method includes receiving a first set of information from a user including one or more preferences of the user and determining availability of a good or a service substantially consistent with the preferences received from the user. The method further includes determining a number of frequent flier miles necessary to purchase the good or service. Determining the number of frequent flier miles needed includes determining at least one of a demand and a cost for the good or service based on information affecting the value of the good or service, as well as establishing a number of miles that correlates to the determined demand or cost. The method also includes sending a signal representative of the number of miles needed to obtain the good or service.
摘要翻译：提供了一种方法，系统和计算机程序，用于赎回频繁飞行里程购买商品或服务。该方法的示例性实施例包括从用户接收包括用户的一个或多个偏好的第一组信息，并确定与从用户接收的偏好基本一致的商品或服务的可用性。该方法还包括确定购买商品或服务所需的频繁旅行里数。确定需要的频繁飞行里程的数量包括基于影响商品或服务的价值的信息来确定商品或服务的需求和成本中的至少一个，以及建立与确定的需求相关联的数英里或成本。该方法还包括发送代表获得商品或服务所需的里程数的信号。

3. 发明授权

US09370492B2 Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers 有权
标题翻译：包含双膦酸盐和改性氨基酸载体的固体药物剂型
公开(公告)号：US09370492B2
公开(公告)日：2016-06-21
申请号：US12504484
申请日：2009-07-16
申请人： Hashim Ahmed , Lewis Bender , Martin Howard Infeld , Shingai Majuru , Wantanee Phuapradit , Navnit Hargovindas Shah , Zhongshui Yu
发明人： Hashim Ahmed , Lewis Bender , Martin Howard Infeld , Shingai Majuru , Wantanee Phuapradit , Navnit Hargovindas Shah , Zhongshui Yu
IPC分类号： A01N57/00 , A61K31/66 , A61K9/20 , A61K9/16 , A61K9/48 , A61K9/50 , A61K31/663 , A61K31/675 , A61K47/32 , A61K9/28 , A61K47/18
CPC分类号： A61K9/2013 , A61K9/1617 , A61K9/2866 , A61K9/48 , A61K9/501 , A61K31/663 , A61K31/675 , A61K47/183 , A61K47/32
摘要： The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone, and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain. The present invention also provides a method for treating these diseases employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.
摘要翻译：本发明提供用于口服给药的新型固体药物剂型，其包含双膦酸盐或其药学上可接受的盐，当双膦酸盐单独口服时，双膦酸盐以不具有治疗效果的量存在，和修饰的氨基酸载体，或其修饰的氨基酸载体的存在量有效地促进胃肠道中双膦酸盐的吸收，使得双膦酸盐具有治疗上的有效性。二膦酸酯与改性氨基酸载体的比率分别为约1:30至约1:1。这些新型固体药物剂型可用于治疗或控制钙代谢中的骨疾病和特定疾病，包括例如骨质疏松症，癌症高钙血症和转移性骨痛的治疗。本发明还提供了使用固体药物剂型治疗这些疾病的方法和制备药物剂型的方法。

4. 发明申请

US20090124639A1 VALACYCLOVIR FORMULATIONS 审中-公开
标题翻译： VALACYCLOVIR公式
公开(公告)号：US20090124639A1
公开(公告)日：2009-05-14
申请号：US12266510
申请日：2008-11-06
申请人： Moses Oyewumi , Shingai Majuru , Lewis Bender , Akm Nasir Uddin
发明人： Moses Oyewumi , Shingai Majuru , Lewis Bender , Akm Nasir Uddin
IPC分类号： A61K31/522 , A61P31/22
CPC分类号： A61K45/06 , A61K31/522 , A61K2300/00
摘要： The present invention relates to valacyclovir formulations having improved bioavailability resulting in better efficacy and/or requiring less frequent administration.
摘要翻译：本发明涉及具有改善的生物利用度导致更好的功效和/或需要较不频繁施用的伐昔洛韦制剂。

5. 发明申请

US20070049557A1 Solid pharmaceutical dosage forms comprising bisphosphonates and modified amino acid carriers 审中-公开
标题翻译：包含双膦酸盐和改性氨基酸载体的固体药物剂型
公开(公告)号：US20070049557A1
公开(公告)日：2007-03-01
申请号：US11498445
申请日：2006-08-03
申请人： Hashim Ahmed , Lewis Bender , Martin Infeld , Shingai Majuru , Wantanee Phuapradit , Navnit Shah , Zhongshui Yu
发明人： Hashim Ahmed , Lewis Bender , Martin Infeld , Shingai Majuru , Wantanee Phuapradit , Navnit Shah , Zhongshui Yu
IPC分类号： A61K31/675 , A61K31/663
CPC分类号： A61K9/2013 , A61K9/1617 , A61K9/2866 , A61K9/48 , A61K9/501 , A61K31/663 , A61K31/675 , A61K47/183 , A61K47/32
摘要： The present invention provides novel solid pharmaceutical dosage forms for oral administration comprising a bisphosphonate, or a pharmaceutically acceptable salt thereof, which bisphosphonate is present in an amount not therapeutically effective when the bisphosphonate is orally administered alone; and a modified amino acid carrier, or a pharmaceutically acceptable salt thereof, which modified amino acid carrier is present in an amount effective to facilitate absorption of the bisphosphonate in the gastrointestinal tract such that the bisphosphonate is therapeutically effective. The ratio of bisphosphonate to modified amino acid carrier is from about 1:30 to about 1:1, respectively. These novel solid pharmaceutical dosage forms are useful in the treatment or control of bone diseases and particular disorders in calcium metabolism, including, for example, osteoporosis, hypercalcaemia of cancer, and the treatment of metastatic bone pain. The present invention also provides a method for treating these diseases employing the solid pharmaceutical dosage forms and a method for preparing the pharmaceutical dosage forms.
摘要翻译：本发明提供用于口服给药的新型固体药物剂型，其包含二膦酸盐或其药学上可接受的盐，当双膦酸盐单独口服给药时，双膦酸盐以不具有治疗效果的量存在; 和经修饰的氨基酸载体的修饰的氨基酸载体或其药学上可接受的盐以有效促进胃肠道中双膦酸盐吸收的量存在，使得双膦酸盐具有治疗上的有效性。二膦酸酯与改性氨基酸载体的比率分别为约1:30至约1:1。这些新型固体药物剂型可用于治疗或控制钙代谢中的骨疾病和特定疾病，包括例如骨质疏松症，癌症高钙血症和转移性骨痛的治疗。本发明还提供了使用固体药物剂型治疗这些疾病的方法和制备药物剂型的方法。

6. 发明申请

US20090123562A1 Pharmaceutical Formulations of Gallium Salts 有权
标题翻译：镓盐制剂
公开(公告)号：US20090123562A1
公开(公告)日：2009-05-14
申请号：US11722618
申请日：2005-12-29
申请人： Lewis Bender , Bavani Shankar , Catherina O'Shaughnessy
发明人： Lewis Bender , Bavani Shankar , Catherina O'Shaughnessy
IPC分类号： A61K33/24 , A61K31/28 , A61K31/195
CPC分类号： A61K33/24 , A61K9/0019 , A61K9/0095 , A61K31/195 , A61K31/351 , A61K47/12 , A61K47/183 , A61K2300/00
摘要： The present invention relates to pharmaceutical formulations containing a pharmaceutically acceptable gallium salt (such as gallium nitrate), a delivery agent, and optionally, one or more chemotherapeutic agents and/or adjunctive chemotherapeutic agents.
摘要翻译：本发明涉及含有药学上可接受的镓盐（例如硝酸镓），递送剂和任选的一种或多种化学治疗剂和/或辅助化学治疗剂的药物制剂。

7. 发明授权

US09345725B2 Pharmaceutical formulations of gallium salts 有权
标题翻译：镓盐的药物制剂
公开(公告)号：US09345725B2
公开(公告)日：2016-05-24
申请号：US11722618
申请日：2005-12-29
申请人： Lewis Bender , Bavani Shankar , Catherina O'Shaughnessy
发明人： Lewis Bender , Bavani Shankar , Catherina O'Shaughnessy
IPC分类号： A61K33/24 , A61K31/195 , A61K31/28 , A61K9/00 , A61K31/351 , A61K47/12 , A61K47/18
CPC分类号： A61K33/24 , A61K9/0019 , A61K9/0095 , A61K31/195 , A61K31/351 , A61K47/12 , A61K47/183 , A61K2300/00
摘要： The present invention relates to pharmaceutical formulations containing a pharmaceutically acceptable gallium salt (such as gallium nitrate), a delivery agent, and optionally, one or more chemotherapeutic agents and/or adjunctive chemotherapeutic agents.
摘要翻译：本发明涉及含有药学上可接受的镓盐（例如硝酸镓），递送剂和任选的一种或多种化学治疗剂和/或辅助化学治疗剂的药物制剂。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式